Abstract
This chapter provides details of studies that describe drug interactions affecting the pharmacokinetics of various antimalarial drugs, including amodiaquine, artemether/lumefantrine, artemisinin derivatives, atovaquone, chloroquine, mefloquine, proguanil, and quinine.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Balian JD, Sukhova N, Harris JW et al (1995) The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 57(6):662–669
Birkett DJ, Rees D, Andersson T et al (1994) In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 37(5):413–420
Coller JK, Somogyi AA, Bochner F (1999) Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms. Br J Clin Pharmacol 48(2):158–167
Cook JA, Randinitis EJ, Bramson CR et al (2006) Lack of a pharmacokinetic interaction between azithromycin and chloroquine. Am J Trop Med Hyg 74(3):407–412
Couet W, Laroche R, Floch JJ et al (1991) Pharmacokinetics of quinine and doxycycline in patients with acute falciparum malaria: a study in Africa. Ther Drug Monit 13(6):496–501
Dong H, Haining RL, Thummel KE et al (2000) Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos 28(12):1397–1400
Ereshefsky L, Riesenman C, Lam YW (1995) Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokinet 29(Suppl 1):10–18
Erickson DA, Mather G, Trager WF et al (1999) Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 27(12):1488–1495
Ernest CS, Hall SD, Jones DR (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312(2):583–591
Ette EI, Brown-Awala EA, Essien EE (1987a) Chloroquine elimination in humans: effect of low-dose cimetidine. J Clin Pharmacol 27(10):813–816
Ette EI, Brown-Awala EA, Essien EE (1987b) Effect of ranitidine on chloroquine disposition. Drug Intell Clin Pharm 21(9):732–724
Falloon J, Sargent S, Piscitelli SC et al (1999) Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. Pharmacotherapy 19(9):1050–1056
Faucette SR, Zhang TC, Moore R et al (2007) Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 320(1):72–80
Foisy MM, Yakiwchuk EM, Hughes CA (2008) Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 42(7):1048–1059
Fontaine F, de Sousa G, Burcham PC et al (2000) Role of cytochrome P450 3A in the metabolism of mefloquine in human and animal hepatocytes. Life Sci 66(22):2193–2212
Funck-Brentano C, Becquemont L, Lenevu A et al (1997) Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther 280(2):730–738
Gbotosho GO, Happi CT, Sijuade A et al (2008) Comparative study of interactions between chloroquine and chlorpheniramine or promethazine in healthy volunteers: a potential combination-therapy phenomenon for resuscitating chloroquine for malaria treatment in Africa. Ann Trop Med Parasitol 102(1):3–9
German PI, Aweeka FT (2008) Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet 47(2):91–102
Hariparsad N, Nallani SC, Sane RS et al (2004) Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 44(11):1273–1281
Ilett KF, Ethell BT, Maggs JL et al (2002) Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos 30(9):1005–1012
Karbwang J, Na-Bangchang K, Back D et al (1991) Effect of ampicillin on mefloquine pharmacokinetics in Thai males. Eur J Clin Pharmacol 40(6):631–633
Karbwang J, Na-Bangchang K, Back DJ et al (1992) Effect of tetracycline on mefloquine pharmacokinetics in Thai males. Eur J Clin Pharmacol 43(5):567–569
Khaliq Y, Gallicano K, Tisdale C et al (2001) Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. Br J Clin Pharmacol 51(6):591–600
Kiang TK, Wilby KJ, Ensom MH (2014) Clinical pharmacokinetic drug interactions associated with artemisinin derivatives and HIV-antivirals. Clin Pharmacokinet 53(2):141–153
Kim KA, Park JY, Lee JS et al (2003) Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res 26(8):631–637
Knodell RG, Browne DG, Gwozdz GP et al (1991) Differential inhibition of individual human liver cytochrome P-450 by cimetidine. Gastroenterology 101:1680–1691
Kolawole JA, Mustapha A, Abdul-Aquye I et al (1999) Effects of cimetidine on the pharmacokinetics of proguanil in healthy subjects and in peptic ulcer patients. J Pharm Biomed Anal 20(5):737–743
Kolawole JA, Mustapha A, Abudu-Aquye I et al (2000) Mefloquine pharmacokinetics in healthy subjects and in peptic ulcer patients after cimetidine administration. Eur J Drug Metab Pharmacokinet 25:165–170
Kumar GN, Rodrigues AD, Buko AM et al (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277(1):423–431
Laine JE, Auriola S, Pasanen M et al (2009) Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica 39(1):11–21
Lamorde M, Byakika-Kibwika P, Mayito J et al (2013) Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment. AIDS 27(6):961–965
Lamson M, MacGregor T, Riska P et al (1999) Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways. Clin Pharmacol Ther 65:137
Lefevre G, Carpenter P, Souppart C et al (2002) Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br J Clin Pharmacol 54(5):485–492
Li XQ, Bjorkman A, Andersson TB et al (2003) Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59:429–442
Madeira M, Levine M, Chang TKH et al (2004) The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6. Drug Metab Dispos 32:460–467
Martinez C, Albet C, Aqundez JA et al (1999) Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther 65(4):369–376
Na-Bangchang K, Karbwang J, Bunnag D et al (1991) The effect of metoclopramide on mefloquine pharmacokinetics. Br J Clin Pharmacol 32(640):641
Nyunt MM, Lu Y, El-Gasim M et al (2012) Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine. Clin Pharmacol Ther 91(5):889–895
Onyeji CO, Toriola TA, Oqunbona FA (1993) Lack of pharmacokinetic interaction between chloroquine and imipramine. Ther Drug Monit 15(1):43–46
Projean D, Baune B, Farinotti R et al (2003) In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos 31(6):748–754
Pukrittayakamee S, Prakongpan S, Wanwimolruk S et al (2003) Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria. Antimicrob Agents Chemother 47(5):1509–1513
Raina RK, Bano G, Amla V et al (1993) The effect of aspirin, paracetamol and analgin on pharmacokinetics of chloroquine. Indian J Physiol Pharmacol 37(3):229–231
Rengelshausen J, Burhenne J, Frohlich M et al (2004) Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. Eur J Clin Pharmacol 60(10):709–715
Ridtitid W, Wongnawa M, Mahatthanatrakul W et al (2000) Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers. J Pharm Pharmacol 52(10):1265–1269
Ridtitid W, Wongnawa M, Mahatthanatrakul W et al (2005) Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers. J Clin Pharm Ther 30(3):285–290
Scarsi KK, Fehintola FA, Ma Q et al (2014) Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. J Antimicrob Chemother 69(5):1370–1376
Soyinka JO, Onyeji CO (2010) Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. Eur J Pharm Sci 39(4):213–218
Soyinka JO, Onyeji CO, Omoruyi SI et al (2009) Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. J Pharm Pharmacol 61(4):439–443
Soyinka JO, Onyeji CO, Omoruyi SI et al (2010) Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. Br J Clin Pharmacol 69(3):262–270
Speirs CJ, Murray S, Boobis AR et al (1986) Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol 22(6):739–743
van Agtmael MA, Van Der Graaf CA, Dien TK et al (1998) The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur J Drug Metab Pharmacokinet 23(3):429–436
van Luin M, Van der Ende ME, Richter C et al (2010) Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. AIDS 24(8):1223–1226
von Moltke LL, Greenblatt DJ, Granda BW et al (2001) Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol 41(1):85–91
Wanwimolruk S, Kaewvichit S, Tanthayaphinant O et al (1991) Lack of effect of oral contraceptive use on the pharmacokinetics of quinine. Br J Clin Pharmacol 31(2):179–181
Wanwimolruk S, Kang W, Coville PF et al (1995) Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. Br J Clin Pharmacol 40(1):87–91
Yeh RF, Gaver VE, Patterson KB et al (2006) Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 42(1):52–60
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Kiang, T.K.L., Wilby, K.J., Ensom, M.H.H. (2015). Pharmacokinetic Drug Interactions Affecting Antimalarials. In: Clinical Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antimalarials. Adis, Cham. https://doi.org/10.1007/978-3-319-10527-7_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-10527-7_4
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-10526-0
Online ISBN: 978-3-319-10527-7
eBook Packages: MedicineMedicine (R0)